At present, surgery is still the main treatment for gastroesophageal junction cancer. At the same time, multimodal comprehensive treatment such as chemotherapy and molecular targeted therapy can effectively alleviate pathological progression, facilitate R0 resection and improve the overall survival of patients.Pembrolizumab, as a PD-1 inhibitor, has been shown to have antitumor activity and a manageable safety profile in gastroesophageal junction cancer.Pembrolizumab combined with chemotherapy has become a research hotspot. However, to date, there is no clinical study related to gastroesophageal junction cancer. In this study, Pembrolizumab combined with FLOT was used as the first-line treatment for gastroesophageal junction cancer, aiming to explore the experience chemotherapy mode for gastroesophageal junction cancer.
1) aged from 18 to 75 years old, including 18 and 80 years old;
1) receiving anti-tumor therapy before enrollment, including but not limited to PD-1 inhibitors, CTLA-4 antibodies, EGFR monoclonal antibodies, EGFR-Tkis, and anti-angiogenic drugs;
Parallel
Pembrolizumab plus chemotherapy (FLOT)
DrugThe experimental group was treated with pembrolizumab combined with FLOT, and the control group was treated with FLOT chemotherapy alone
objective response rate
objective response rate
duration of response
duration of response
disease control rate
disease control rate
time to response
time to response
overall surival
overall surival
Click on the lead sponsor to view all of their trials.
xiaohua li
Lead sponsor
Xijing Hospital of Digestive Diseases
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
